Elizabeth Berry-Kravis established the Fragile X Clinic and Research Program at Rush University Medical Center in 1992, which now provides care to more than 700 individuals with FXS. She researches FXS and other neurogenetic conditions, including outcome measures, biomarkers, natural history studies and clinical trials in FXS, Phelan-McDermid Syndrome, Niemann-Pick type C disease, Angelman syndrome, Rett syndrome, and Down syndrome. She has led the translational effort to develop new models for targeted treatment for FXS.